生物学标志物预测抗肿瘤坏死因子-α单克隆抗体治疗炎症性肠病疗效的研究进展  

Progress of Research on Biomarkers in Predicting Efficacy of Anti-tumor Necrosis Factor-α Monoclonal Antibody in Treatment of Inflammatory Bowel Disease

作　　者：田嘉慧 徐晨静 张红杰[1] TIAN Jiahui;XU Chenjing;ZHANG Hongjie(Department of Gastroenterology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,210029)

机构地区：[1]南京医科大学第一附属医院消化内科,210029

出　　处：《胃肠病学》2022年第1期42-46,共5页Chinese Journal of Gastroenterology

基　　金：国家自然科学基金(82070568)。

摘　　要：抗肿瘤坏死因子(TNF)-α单克隆抗体作为治疗炎症性肠病患者的一线药物,其应答情况越来越受到关注。药物浓度监测和抗药抗体监测已在临床广泛应用,但仍缺乏指标在开始药物治疗前预测抗TNF-α治疗的药物应答,以指导治疗方案的选择。目前已有研究表明部分基线水平生物学标志物能预测抗TNF-α药物的应答。本文就生物学标志物预测抗TNF-α单克隆抗体治疗炎症性肠病疗效的研究进展作一综述。Anti-tumor necrosis factor(TNF)-αmonoclonal antibody is a first-line treatment for inflammatory bowel disease,and its therapeutic response has attracted more and more attention.Although therapeutic drug monitoring and anti-drug antibody monitoring have been widely used in clinic,however,there are no laboratory indicators that can predict the therapeutic response to anti-TNF-αbefore the drug treatment,so as to provide a guidance of selecting therapeutic drug.Studies have shown that some baseline biomarkers can predict the therapeutic response to anti-TNF-α.This article reviewed the progress of research on biomarkers in predicting efficacy of anti-TNF-αmonoclonal antibody in treatment of inflammatory bowel disease.

关 键 词：炎症性肠病 CROHN病 结肠炎 溃疡性 肿瘤坏死因子α 生物学标记 治疗 

分 类 号：R574[医药卫生—消化系统]